H. TONBUL Et Al. , "In vivo Evaluation of Doxorubicin and Elacridar Co-Loaded PLGA/Silica Hybrid Nanoparticles Against Multidrug Resistant Breast Cancer," 9 th BBBB International Conference on Pharmaceutical Sciences , Ljubljana, Slovenia, 2022
TONBUL, H. Et Al. 2022. In vivo Evaluation of Doxorubicin and Elacridar Co-Loaded PLGA/Silica Hybrid Nanoparticles Against Multidrug Resistant Breast Cancer. 9 th BBBB International Conference on Pharmaceutical Sciences , (Ljubljana, Slovenia).
TONBUL, H., ŞAHİN, A., ÖZTÜRK, S. C., ULTAV, G., ESENDAĞLI, G., & ÇAPAN, Y., (2022). In vivo Evaluation of Doxorubicin and Elacridar Co-Loaded PLGA/Silica Hybrid Nanoparticles Against Multidrug Resistant Breast Cancer . 9 th BBBB International Conference on Pharmaceutical Sciences, Ljubljana, Slovenia
TONBUL, HAYRETTİN Et Al. "In vivo Evaluation of Doxorubicin and Elacridar Co-Loaded PLGA/Silica Hybrid Nanoparticles Against Multidrug Resistant Breast Cancer," 9 th BBBB International Conference on Pharmaceutical Sciences, Ljubljana, Slovenia, 2022
TONBUL, HAYRETTİN Et Al. "In vivo Evaluation of Doxorubicin and Elacridar Co-Loaded PLGA/Silica Hybrid Nanoparticles Against Multidrug Resistant Breast Cancer." 9 th BBBB International Conference on Pharmaceutical Sciences , Ljubljana, Slovenia, 2022
TONBUL, H. Et Al. (2022) . "In vivo Evaluation of Doxorubicin and Elacridar Co-Loaded PLGA/Silica Hybrid Nanoparticles Against Multidrug Resistant Breast Cancer." 9 th BBBB International Conference on Pharmaceutical Sciences , Ljubljana, Slovenia.
@conferencepaper{conferencepaper, author={HAYRETTİN TONBUL Et Al. }, title={In vivo Evaluation of Doxorubicin and Elacridar Co-Loaded PLGA/Silica Hybrid Nanoparticles Against Multidrug Resistant Breast Cancer}, congress name={9 th BBBB International Conference on Pharmaceutical Sciences}, city={Ljubljana}, country={Slovenia}, year={2022}}